"We're entering an era of more trauma-informed care, and trying to be sensitive to the fact that some of these invasive procedures can be a trigger for people because they're in that moment of feeling helpless and they don't have really a lot of control over the situation," says Heidi J. Rayala, MD.
"If you don't do a repeat curve assessment with each series of injections, you're possibly going to be missing the best location to do the injections," says Landon Trost, MD.
"The genomics assay was using biopsy tissue to help patients make decisions for the treatment choices. We also tested the effect of the assay on provider choice," says Adam B. Murphy, MD, MBA, MSCI.
"There are a lot of questions and issues regarding [topics] like body image and sexual function, and things like that, that also, being a woman in this role, I feel like they feel comfortable asking me those questions," says Bree Duncan, RN, BSN.
"Then [we] also started looking at somatic testing, because if you only stop at germline testing, you miss another 50% of patients who would have somatic alterations who have resistant prostate cancer," says Neal D. Shore, MD, FACS.
"In 2021, we started collecting data on opioids prescribed at discharge to see whether or not patients did or did not get prescribed opioids," says Katherine Wang, MD.
"My goal is to always meet them there in clinic, and then just start that relationship, in a sense of, I'm there for whatever they need," says Bree Duncan, RN, BSN.
“Private equity allows an opportunity to provide improved scale with large organization,” says Scott B. Sellinger, MD, FACS.
“[Although] not yet ready for prime time, ctDNA is being investigated as a very promising non-invasive plasma biomarker of invasive or advanced-stage upper tract urothelial carcinoma,” says Heather L. Huelster, MD.
"The viability and survivability of practices is in jeopardy," says Bradley Gill, MD.
"I think the take-home message is that surgery is safe, even for these challenging surgical cases after this therapy," says Jason Scovell, MD.
"In the study, when taking into account other factors, such as the socioeconomic factors that are available to us in the NCDB, we find that African American and Hispanic patients are about 20% less likely to receive immune checkpoint inhibition for advanced RCC," says Solomon L. Woldu, MD.
"One of the biggest surprises was just how ubiquitous prescribing narcotics in all phases were, from intraoperatively to the PACU to postoperatively," says Aaron A. Laviana, MD, MBA.
“The efficacy analysis for all patients based upon a central pathology review revealed a complete response at any time point of 75.7%,” says Mark D. Tyson, MD, MPH.
"Specifically when we stratified by tertiles, we saw that at 15 years there was a significant difference in cancer-specific survival for those who had a high MMAI score vs lower MMAI scores," says Eric Li, MD.
"All forms of cancer start out by genetic changes in the DNA that cause cancer, so genetic testing becomes very important," says William J. Catalona, MD.
"We're one of the first to look at hypogonadism, or low testosterone, as a marker for both frailty and also as a biomarker for how these patients do after surgery," says Daniel Greenberg, MD.
"The Inflation Reduction Act has changed the landscape, and we really still don't understand what those implications are going to be," says Mara R. Holton, MD.
"We need improved efficiency. Part of that is being as optimal in our settings and in our techniques that we can," says Smita De, MD, PhD.
"We found that about 25% of these men had either sought treatment for a men's health issue or a sexual issue or had wanted to seek care," says Daniel Greenberg, MD.
Laura Bukavina, MD, MPH, offers a preview of noteworthy bladder and kidney cancer research to be presented at this year's Society of Urologic Oncology Annual Meeting.
"We knew that the MS or momentary squeeze pump, originally designed at AMS was a fine device, but it did have some issues. We thought we could make it even better," says Ronald A. Morton, MD.
Kelly L. Stratton, MD, FACS, highlights 5 noteworthy prostate cancer abstracts set to be presented at the 24th Annual Meeting of the Society of Urologic Oncology.
"What we found is that overall, it was relatively effective at providing advice to patients on these pretty commonly encountered questions," says Sharath Reddy, MD.
“Health literacy pushed people towards active surveillance, which I thought was an interesting finding,” says Adam B. Murphy, MD, MBA, MSCI.
"I think there have been a lot of what I would consider incremental improvements over the past few years," Smita De, MD, PhD.
“The use of perioperative subcutaneous heparin should be considered in all patients that are undergoing IPP surgery,” says Thairo Pereira, MD.
“We have definitely seen significant trends toward transparency in hospital pricing, and in regulations designed to promote that, as well as PBM reform,” says Mara R. Holton, MD.
"In general, I think there's a tremendous amount of variability in terms of how sexual medicine specialists treat patients who have had intimacy issues relating to robotic prostatectomy," says Stanton Honig, MD.
"We as a specialty have to do a better job of educating our colleagues and referring docs," says Roger R. Dmochowski, MD, MMHC, FACS
